Bridging continual reassessment method for phase I clinical trials in different ethnic populations
- 28 January 2015
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 34 (10) , 1681-1694
Abstract
Accumulating evidence shows that the conventional one‐size‐fits‐all dose‐finding paradigm is problematic when applied to different ethnic populations. Because of inter‐ethnic heterogeneity, the dosage established in a landmark trial for a certain population may not be generalizable to a different ethnic population, and a follow‐up bridge trial is often needed to find the maximum tolerated dose for the new population. We propose the bridging continual reassessment method (B‐CRM) to facilitate dose finding for such follow‐up bridge trials. The B‐CRM borrows information from the landmark trial through a novel estimate of the dose‐toxicity curve and accommodates the inter‐ethnic heterogeneity using the Bayesian model averaging approach. Extensive simulation studies show that the B‐CRM has desirable operating characteristics with a high probability to select the target dose. This article focuses on ethnic heterogeneity, but the proposed method can be directly used to handle other types of patient heterogeneity, for example, patient subgroups defined by prognostic factors or biomarkers. The software to implement the B‐CRM design is available for free download at http://odin.mdacc.tmc.edu/~yyuan/. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
Funding Information
- NCI (CA154591)
- NCI (CA016672)
- NCI (5P50CA098258)
This publication has 31 references indexed in Scilit:
- A Predictive Bayesian Approach to the Design and Analysis of Bridging StudiesJournal of Biopharmaceutical Statistics, 2012
- Statistical Methods for Bridging StudiesJournal of Biopharmaceutical Statistics, 2012
- A Bayesian Approach for Inference from a Bridging Study with Binary OutcomesJournal of Biopharmaceutical Statistics, 2012
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2012
- Application of the continual reassessment method to a phase I dose‐finding trial in Japanese patients: East meets WestStatistics in Medicine, 2011
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical TrialsJournal of the American Statistical Association, 2009
- Model calibration in the continual reassessment methodClinical Trials, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Critical aspects of the Bayesian approach to phase I cancer trialsStatistics in Medicine, 2008
- Model Selection and Accounting for Model Uncertainty in Graphical Models Using Occam's WindowJournal of the American Statistical Association, 1994